Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-06-07

Clinical Trial Update: Sunitinib for Advanced Thymus Cancer Following Earlier Treatment [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sunitinib in advanced thymus cancers (thymoma and thymus neoplasms) has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sunitinib (sunitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Thymoma, Thymus Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2022-06-07